iTeos Therapeutics, Inc. (NASDAQ:ITOS) Stock Position Decreased by AQR Capital Management LLC

AQR Capital Management LLC trimmed its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 66.0% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 29,298 shares of the company’s stock after selling 56,870 shares during the quarter. AQR Capital Management LLC owned approximately 0.08% of iTeos Therapeutics worth $435,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Dimensional Fund Advisors LP raised its position in iTeos Therapeutics by 14.8% during the second quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock valued at $13,481,000 after buying an additional 117,159 shares during the period. American Century Companies Inc. grew its stake in iTeos Therapeutics by 26.5% during the 2nd quarter. American Century Companies Inc. now owns 46,322 shares of the company’s stock valued at $687,000 after acquiring an additional 9,717 shares in the last quarter. Candriam S.C.A. acquired a new position in shares of iTeos Therapeutics in the 2nd quarter valued at about $7,558,000. Victory Capital Management Inc. lifted its position in shares of iTeos Therapeutics by 17.7% in the second quarter. Victory Capital Management Inc. now owns 110,389 shares of the company’s stock worth $1,638,000 after purchasing an additional 16,629 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in shares of iTeos Therapeutics by 8.5% in the second quarter. Rhumbline Advisers now owns 44,861 shares of the company’s stock worth $666,000 after purchasing an additional 3,513 shares in the last quarter. 97.16% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently issued reports on ITOS shares. JPMorgan Chase & Co. cut their price objective on iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating for the company in a report on Monday, August 12th. HC Wainwright reaffirmed a “buy” rating and issued a $46.00 target price on shares of iTeos Therapeutics in a research report on Monday, September 16th. Wells Fargo & Company initiated coverage on iTeos Therapeutics in a report on Tuesday, August 13th. They set an “overweight” rating and a $31.00 price target for the company. Finally, Wedbush restated an “outperform” rating and issued a $21.00 price objective on shares of iTeos Therapeutics in a report on Thursday, August 8th.

iTeos Therapeutics Price Performance

Shares of iTeos Therapeutics stock opened at $9.42 on Wednesday. The firm has a 50 day simple moving average of $13.59 and a 200 day simple moving average of $14.43. iTeos Therapeutics, Inc. has a fifty-two week low of $8.45 and a fifty-two week high of $18.75. The firm has a market cap of $340.28 million, a P/E ratio of -2.49 and a beta of 1.36.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.86. The business had revenue of $35.00 million during the quarter, compared to analyst estimates of $4.20 million. On average, sell-side analysts expect that iTeos Therapeutics, Inc. will post -3.64 EPS for the current year.

iTeos Therapeutics Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.